TORONTO, June 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation.

TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation.